Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors.
Gestational age
kidney injury biomarkers
maternal hypertension
patent ductus arteriosus
very-low-birth-weight preterm infants
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
14
01
2020
revised:
27
01
2020
accepted:
29
01
2020
entrez:
2
5
2020
pubmed:
2
5
2020
medline:
13
2
2021
Statut:
ppublish
Résumé
Acute kidney injury is an important cause of mortality in very-low-birth-weight (VLBW) preterm infants. As in the general population, the detection of renal damage cannot rely on the measurement of serum creatinine, since it has been demonstrated to be a weak predictor and a delayed indicator of kidney function deterioration. However, several candidate biomarkers have failed to prove sufficient specificity and sensitivity for a routine clinical use because of the poor awareness of their biological role. This study was aimed to investigate the impact of different maternal and neonatal conditions on several renal biomarkers in VLBW preterm infants during the first week of life. Preterm infants<32 weeks' gestation and <1500g were enrolled. We measured urinary biomarkers kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, epidermal growth factor (EGF) and osteopontin (OPN) on the 1 Thirty-tree infants were included. The multivariate analysis showed a significant association between gestational age, the presence of patent ductus arteriosus, antenatal maternal hypertension and the levels of urinary biomarkers. There is a possible relation between early biomarkers of renal injury and antenatal, perinatal and post-natal characteristics in VLBW preterm infants during the first week of life.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Acute kidney injury is an important cause of mortality in very-low-birth-weight (VLBW) preterm infants. As in the general population, the detection of renal damage cannot rely on the measurement of serum creatinine, since it has been demonstrated to be a weak predictor and a delayed indicator of kidney function deterioration. However, several candidate biomarkers have failed to prove sufficient specificity and sensitivity for a routine clinical use because of the poor awareness of their biological role. This study was aimed to investigate the impact of different maternal and neonatal conditions on several renal biomarkers in VLBW preterm infants during the first week of life.
PATIENTS AND METHODS
METHODS
Preterm infants<32 weeks' gestation and <1500g were enrolled. We measured urinary biomarkers kidney injury molecule 1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, epidermal growth factor (EGF) and osteopontin (OPN) on the 1
RESULTS
RESULTS
Thirty-tree infants were included. The multivariate analysis showed a significant association between gestational age, the presence of patent ductus arteriosus, antenatal maternal hypertension and the levels of urinary biomarkers.
CONCLUSION
CONCLUSIONS
There is a possible relation between early biomarkers of renal injury and antenatal, perinatal and post-natal characteristics in VLBW preterm infants during the first week of life.
Identifiants
pubmed: 32354927
pii: 34/3/1333
doi: 10.21873/invivo.11910
pmc: PMC7279835
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1333-1339Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Pediatr Res. 2008 Oct;64(4):423-8
pubmed: 18552711
Semin Fetal Neonatal Med. 2017 Apr;22(2):83-89
pubmed: 28109705
Int J Nephrol Renovasc Dis. 2013 Oct 02;6:181-6
pubmed: 24124387
Kidney Int. 2016 Feb;89(2):429-38
pubmed: 26398494
Neonatology. 2012;101(4):260-6
pubmed: 22222353
Pediatr Nephrol. 2015 Nov;30(11):2037-44
pubmed: 26001700
Obstet Gynecol. 2019 Jan;133(1):e1-e25
pubmed: 30575675
BMC Pediatr. 2017 Jan 10;17(1):7
pubmed: 28068947
Pediatr Nephrol. 2009 May;24(5):991-7
pubmed: 19238451
Pediatr Res. 2011 Oct;70(4):379-83
pubmed: 21691251
In Vivo. 2015 Jan-Feb;29(1):117-21
pubmed: 25600539
Pediatr Res. 2016 Aug;80(2):218-23
pubmed: 27055185
JAMA Pediatr. 2017 Jan 1;171(1):83-88
pubmed: 27893069
In Vivo. 2019 Nov-Dec;33(6):2199-2204
pubmed: 31662556
Pediatr Nephrol. 2009 Feb;24(2):265-74
pubmed: 19082634
Histochem J. 1999 Jul;31(7):433-41
pubmed: 10475571
Pediatr Nephrol. 2016 Jul;31(7):1179-88
pubmed: 26862052
Nat Rev Nephrol. 2012 Feb 28;8(5):265-74
pubmed: 22371245
Adv Clin Exp Med. 2019 Dec;28(12):1691-1695
pubmed: 31851791
J Pediatr. 2011 Dec;159(6):907-12.e1
pubmed: 21784446
Pediatr Res. 2010 Jun;67(6):636-40
pubmed: 20496473
Arch Dis Child Fetal Neonatal Ed. 2018 Nov;103(6):F547-F553
pubmed: 29208666
J Reprod Immunol. 2015 Nov;112:111-4
pubmed: 26454417
Arch Med Sci. 2018 Oct;14(6):1381-1386
pubmed: 30393493
Lancet. 2013 Jul 20;382(9888):273-83
pubmed: 23727166
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S21-S32
pubmed: 31502686
BMC Pediatr. 2017 Feb 21;17(1):59
pubmed: 28222717
J Clin Diagn Res. 2015 Jun;9(6):SC08-11
pubmed: 26266178
Pediatr Nephrol. 2018 Aug;33(8):1365-1374
pubmed: 29532235
Curr Opin Crit Care. 2002 Dec;8(6):509-14
pubmed: 12454534
Am J Perinatol. 2013 May;30(5):347-52
pubmed: 23023560
Semin Fetal Neonatal Med. 2017 Apr;22(2):90-97
pubmed: 28034548
Semin Fetal Neonatal Med. 2018 Apr;23(2):126-132
pubmed: 29229486
Nat Biotechnol. 2010 May;28(5):436-40
pubmed: 20458311
Semin Perinatol. 2017 Oct;41(6):332-337
pubmed: 28823579
SAGE Open Med. 2019 Apr 10;7:2050312119843700
pubmed: 31007914
In Vivo. 2019 Sep-Oct;33(5):1573-1580
pubmed: 31471407